James F. Holland, MD

James F. Holland, MD
Distinguished Professor of Neoplastic Diseases, Mount Sinai Medical Center, New York, New York

James F. Holland, MD | Class of 2013

A pioneer in clinical cancer research, Dr. Holland’s contributions to the field include his role at the National Cancer Institute in 1953, where he began the first combination chemotherapy program in acute leukemia. His subsequent work with Tom Frei, J Freireich, Jean Bernard and members of Acute Leukemia Group B on acute lymphoblastic leukemia in children resulted in its transformation from incurability to an over 80 percent survival rate. He constructed the 7 and 3 regimen for acute myelocytic leukemia which is used worldwide and first identified cisplatin for testicular cancer and doxorubicin for osteosarcoma. Novel research on adjuvant and neo-adjuvant chemotherapy in these diseases and in breast and ovarian cancers influenced treatment protocols.

He and colleagues have recently described HMTV, the human mammary tumor virus, present in 40 percent of American women’s breast cancers that is 90 to 95 percent homologous to MMTV, the cause of breast cancer in mice. Dr. Holland also collaborated with Tom Frei to edit Cancer Medicine, an important reference that covers science and clinical applications for cancers. This specialty text, now in its eighth edition with additional co-editors, continues to influence oncologists worldwide.

Career Highlights

1997 Doctor of Science, honoris causa, State University of New York at Buffalo
1986 First Return of the Child Award, Leukemia Society of America
1985-1993 Director, The Derald H. Ruttenberg Cancer Center, Mount Sinai Medical Center
1983 Co-Founder AORTIC, the African Organization for Research and Training in Cancer
1982 David A. Karnofsky Memorial Award, ASCO
1981 American Cancer Society National Award (Gold Medal)
1976 President, American Society of Clinical Oncology (ASCO)
1973-1993 Professor and Chairman, Department of Neoplastic Diseases, Mount Sinai School of Medicine
1972 Lasker Award for Cancer Chemotherapy
1970-1971 President, AACR
1963-1981 Chairman, Acute Leukemia Group B (ALGB), (later the Cancer and Leukemia Group B (CALGB), now the Alliance for Clinical Trials in Oncology (ACTION), National Cancer Institute
1954-1973 Chief of Medicine A and Director, Cancer Clinical Research Center, Roswell Park Cancer Institute
1953-1954 National Cancer Institute, Surgeon, U.S. Public Health Service
1949-1951 Captain, U.S. Army Medical Corps
1947 MD, Columbia University College of Physicians and Surgeons